Abstract
ObjectivesPatients under rituximab therapy are at high risk for a severe COVID-19 disease course. Humoral immune responses to SARS-CoV-2 vaccination are vastly diminished in B-cell-depleted patients, even after a third...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have